RxDoctor Payments Data

Barbara Hughes, NP

Family · Waukesha, WINPI 1457911265

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,671 of the $4,412 with a category attached, or 60.5%. 10 manufacturers reported payments, led by Medtronic at 42.5% of the total. Reporting peaked in 2024 at $2,070 and has fallen 55.0% since, to $932 in 2025. Among family clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,412in general payments, 2019–2025

Across 44 payments — averaging $100.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$807
  • Biohaven Pharmaceuticals, Inc.$480
  • AstraZeneca$465
  • Biohaven Pharmaceutical Holding Company Ltd.$250
  • Lundbeck LLC$250
  • plus $287 from 4 others

What the payments were for

  • Travel & lodging$1,74139%
  • Food & beverage$2,67161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,412 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$20,570
Medicare patients
150
Services billed
256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant67$68,252
Emgality PenGalcanezumab-Gnlm55$50,236
Nurtec OdtRimegepant Sulfate39$47,817
Abilify MaintenaAripiprazole14$43,032
QuliptaAtogepant18$19,793
Emgality SyringeGalcanezumab-Gnlm15$11,655
EliquisApixaban13$7,885
Levetiracetam128$3,432
Gabapentin135$3,327
Topiramate65$1,499
Lamotrigine51$1,481
Lacosamide17$1,440
Donepezil Hcl OdtDonepezil Hcl36$1,395
Carbidopa-LevodopaCarbidopa/Levodopa43$1,346
Duloxetine Hcl45$1,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Eliquis$128$55,70252 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.

Other family in Waukesha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →